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Abstract  3 
 4 
Pregnancy-Specific Glycoproteins (PSGs) are secreted members of the carcinoembryonic 5 
antigen cell adhesion molecule (CEACAM) family, which are expressed by trophoblast cells. 6 
PSGs may modulate maternal immune and platelet responses during pregnancy. Until now 7 
PSGs are only found in species which have a highly invasive (hemochorial) placentation 8 
including humans, mice and rats. Surprisingly, analyzing the CEACAM gene family of the 9 
horse, which has a less invasive epitheliochorial placenta, we identified equine CEACAM 10 
family members that seem to be related to PSGs of rodents and primates. We identified seven 11 
genes that encode secreted PSG-like CEACAMs. Phylogenetic analyses indicate that they 12 
evolved independently from an equine CEACAM1-like ancestor rather than from a common 13 
PSG-like ancestor with rodents and primates. Significantly, expression of PSG-like genes 14 
(CEACAM44, CEACAM48, CEACAM49, CEACAM55) was found in trophoblast cells such 15 
as purified chorionic girdle cells and endometrial cup cells. Chorionic girdle cells are highly 16 
invasive trophoblast cells which invade the endometrium of the mare where they form 17 
endometrial cups andare in close contact with maternal immune cells. Therefore despite some 18 
fundamental differences the microenvironment of invasive equine trophoblast cells has striking 19 
similarities to the microenvironment of trophoblast cells in hemochorial placentas, suggesting 20 
that equine PSG-like CEACAMs and rodent and primate PSGs have undergone convergent 21 
evolution as an adaption to a highly specific microenvironment. This is supported by our finding 22 
that, similar to certain rodent and human PSGs, equine PSG-like CEACAM49 has anti-platelet 23 
activity. Our results have implications for understanding the evolution of PSGs and their 24 






The placenta has pivotal functions in facilitating nutrient exchange between mother and fetus and in 3 
protecting the fetus from the maternal immune system (Hemberger 2013). This implies that there may 4 
be common placenta-specific genes expressed in all placental mammals. However, the composition of 5 
placenta-specific genes appears to be highly species-specific, partly due to the expansion of different 6 
gene families in different mammalian lineages (Rawn & Cross 2008). Indeed, placentas are quite diverse 7 
among mammals in their structure, endocrine function and immunology. For example, the extent of 8 
invasion of the uterus by placental trophoblast cells can range from no invasion (as in epitheliochorial 9 
placentation) to very extensive invasion (as in hemochorial placentation) where fetal trophoblast cells 10 
are in direct contact with maternal blood (Moffett & Loke 2006).  11 
 12 
In the highly invasive placentas of the human and laboratory animals such as mice, rats and rabbits, 13 
potent tolerance mechanisms are required to avoid deleterious maternal immune and thrombotic 14 
responses to the semiallogeneic fetus (von Rango 2008). Many mechanisms have been proposed to 15 
explain the maternal-fetal immune tolerance since Medawar and colleagues first discussed the idea of 16 
maternal-fetal tolerance (Trowsdale & Betz 2006, Schumacher et al. 2014).  17 
 18 
One protein family which is thought to be involved in the regulation of the immune and platelet 19 
responses at the maternal-fetal interface is the Pregnancy-specific glycoprotein family (PSG). PSGs 20 
were originally isolated from the circulation of pregnant women (Bohn 1971). In humans, the 21 
concentration of PSGs in the bloodstream increases exponentially until term, thereby comprising the 22 
most abundant fetal proteins in maternal blood (Lin et al. 1974). PSGs are placentally secreted proteins 23 
and part of the carcinoembryonic antigen (CEA) family, which by itself is a member of the 24 
immunoglobulin superfamily. The CEA gene family comprises a group of “conserved” CEACAMs, and 25 
a larger group of CEACAM1 paralogs.  The “conserved” CEACAMs include CEACAM1 itself, 26 
CEACAM16, CEACAM18, CEACAM19 and CEACAM20 (Kammerer & Zimmermann 2010). The PSG 27 
genes belong to the CEA-related cell adhesion molecule 1 (CEACAM1) paralogs of the CEA gene 28 
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family. PSGs are secreted CEACAMs expressed in a predominantly trophoblast-specific manner. 1 
 2 
PSGs are one of the most rapidly evolving protein families in humans (Zebhauser et al. 2005, Chuong 3 
et al. 2010). Probably as a consequence, PSGs differ considerably in structure between primates and 4 
rodents. Human PSGs are composed of one N-terminal immunoglobulin variable (IgV)-like domain (N 5 
domain) followed by two to three Ig constant (IgC)-like domains of two different types (named A and 6 
B), whereas rodent PSGs contain 2 - 9 consecutive N domains followed by one IgC-like domain 7 
(McLellan et al. 2005). In addition, the expansion of PSG genes took place in two different loci in higher 8 
primates and rodents (Kammerer & Zimmermann 2010). There exist 11 and 17 different PSG genes in 9 
humans and mice, respectively. Recently it was demonstrated that human PSGs are expressed in 10 
trophoblast cells due to the activation of various transcription factors including Sp1 (specificity protein 11 
1), KLF4 (Krüppel-like transcription factor 4) and RXRα (retinoid X receptor alpha) (Camolotto et al. 12 
2010, Hubert et al. 2010). If this is also the case for rodent PSGs is not known. 13 
 14 
Low PSG levels in maternal circulation are associated with certain pregnancy complications such as 15 
intrauterine growth retardation, preeclampsia and spontaneous abortion (Towler et al. 1977, Karg et al. 16 
1981, Silver et al. 1993, Arnold et al. 1999). This may be due to loss of the immunoregulatory and anti-17 
thrombotic functions of PSGs. PSGs induce monocytes to synthesize anti-inflammatory cytokines and 18 
promote alternative macrophage activation which correlates with the shift from Th1- to Th2-mediated 19 
immunological responses (Wessells et al. 2000, Snyder et al. 2001, Motran et al. 2003). In addition 20 
elevated PSG levels are correlated with improved symptoms of rheumatoid arthritis (Fialova et al. 1991) 21 
and multiple sclerosis (Bebo & Dveksler 2005). PSGs also exhibit anti-thrombotic activity by binding 22 
integrin αIIbβ3 and inhibiting the platelet – fibrinogen interaction (Shanley et al. 2013). To our current 23 
knowledge, PSGs evolved exclusively in mammals with hemochorial placentation. In cattle 24 
(epitheliochorial placenta) and dogs (endotheliochorial placenta), PSGs did not evolve (Kammerer et al. 25 
2004, Kammerer et al. 2007).  26 
 27 
However, here we show that PSGs evolved in the horse. The horse has an epitheliochorial placenta, 28 
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which represents the least invasive form of placentation. However, a subpopulation of trophoblast cells 1 
(chorionic girdle cells) differentiates to a highly invasive phenotype (Allen et al. 1973, Lunn et al. 1997). 2 
Around day 35 post-ovulation these binucleated, well-differentiated, eCG-secreting cells invade the 3 
endometrium. and build the endometrial cups which reach their maximum size and hormone-secreting 4 
capacity between day 60 and 70 of gestation (Allen 2001).  During invasion, chorionic girdle cells 5 
express conventional MHC class I antigens and are recognized but not initially destroyed by the maternal 6 
immune system (Donaldson et al. 1990, Noronha & Antczak 2010). The endometrial cups have a restricted 7 
lifespan and the cells die around days 80-100 of pregnancy, although the exact mechanisms that lead to their 8 
destruction remain poorly understood. In this report, we show that equine PSGs are expressed in Chorionic 9 
girdle cells as well as in endometrial cups and that equine PSGs have a similar functional activity to 10 
human and rodent PSGs. Future work is in progress to examine the immunomodulatory functions of 11 
equine PSGs. 12 
 13 
Material and Methods 14 
Cells and tissues 15 
Different equine tissue samples including salivary gland, trachea, lung, kidney, renal pelvis, skin, fat, 16 
pancreas, vein, liver, spleen, lymph node, tongue, esophagus, stomach, duodenum, jejunum, ileum, 17 
cecum, colon, rectum, ovary, uterus, cervix, udder, oviduct, bladder, vulva were collected from freshly 18 
slaughtered healthy horses and flash-frozen in liquid nitrogen. Peripheral blood mononuclear cells 19 
(PBMCs) were isolated from blood, which was collected for diagnostic purpose, of healthy horses by 20 
density-gradient centrifugation through Ficoll-Paque 1.077 g/l (GE Healthcare, Freiburg, Germany).  21 
 22 
Stimulation of PBMC with 200 U/ml human IL-2 for the indicated time was performed at a 23 
concentration of 5 x 105 cells/ml in RPMI-1640 supplemented with 10% fetal calf serum (FCS "Gold"; 24 
PAA Laboratories, Coelbe, Germany), 2 mM L-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, 25 
non-essential amino acids and 1 mM sodium pyruvate (GIBCO/Invitrogen, Karlsruhe, Germany). 26 
Endometrial cup tissue samples were obtained from a 65 days pregnant, sedated mare by transcervical 27 
hysteroscopy via an endoscopy biopsy forceps under visual control. The procedure was performed to 28 
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initiate the abortion of the unwanted fetus. Tissue samples were immediately transferred to RNAlater 1 
(Qiagen, Hilden, Germany). Relevant tissue collection was approved by animal use committee of local 2 
authorities (LALLF Rostock; 7221.3-2.1-011/13). Generation of tissue from earlier stages of pregnancy 3 
and isolation and culture of chorionic girdle trophoblast cells has been previously described (Cabrera-4 
Sharp et al. 2014).  In brief, mares aged 3–7 years were maintained at the Royal Veterinary College and 5 
animal care was performed in accordance with the Animals (Scientific Procedures) Act 1986 guidelines 6 
set by the Home Office and the Ethics Committee of the Royal Veterinary College. The reproductive 7 
cycle of 5 mares was manipulated, and pregnancies were established using semen from 3 stallions. 8 
Conceptuses were recovered by nonsurgical uterine lavage with established methods between days 31 9 
and 34 of pregnancy. Conceptuses were microdissected into chorionic girdle, allantochorion, chorion, 10 
yolk sac, bilaminar omphalopleure, and fetus and tissue snap frozen in liquid nitrogen. To gain a pure 11 
population of trophoblast cells, strips of chorionic girdle were placed into DMEM, and the chorionic 12 
girdle trophoblast cells were gently removed from basement membrane and underlying avascular 13 
mesodermal cell layer and cultured as per published methods (de Mestre et al. 2008). Tissues from 4 14 
independent pregnancies and trophoblast cells isolated from an additional 5 independent pregnancies 15 
were used with the gestational age and passage number (0-3) of the cultured cells indicated in the figure 16 
legend.   17 
 18 
Identification and prediction of equine CEACAMs 19 
In order to identify all genes of the equine CEA gene family cluster we screened both the whole genome 20 
shot gun sequence (WGS) database at NCBI (http://www.ncbi.nlm.nih.gov) and the ensemble genome 21 
build at (http://www.ensemble.org) by running respective BLAST search tools using nucleotide 22 
sequences of all CEACAM exons of human, mouse, dog and cattle. Exon/Intron structures were 23 
predicted manually.  24 
 25 
Reverse transcription-polymerase chain reaction analysis 26 
Total RNA extraction from tissue was performed using the RNeasy kit (Qiagen, Hilden, Germany). 27 
RNA was isolated from cultured trophoblast cells using RNAbee (Amsbio, Abingdon, United 28 
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Kingdom). RNAbee was added directly to the culture well and cells scraped before removal to an 1 
Eppendorf tube and RNA extracted as described by the manufacturer. 500ng to one microgram of total 2 
RNA was used for cDNA synthesis by reverse transcription (RT) using the AMV Reverse Transcriptase 3 
(Promega, Mannheim, Germany). The RT product was amplified by polymerase chain reaction (PCR) 4 
with Taq polymerase (Fermentas, thermos Scientific, VWR International Germany GmbH, Darmstadt, 5 
Germany). After an initial denaturation step at 95°C for 45 s, 35 PCR cycles (denaturation: 95°C, 30 s; 6 
annealing: 60°C, 1 min; extension: 72°C, 1.5 min) and a final extension step at 72°C for 15 min were 7 
performed. Primers were designed according to our sequence predictions based on sequences identified 8 
in various NCBI data bases and based on newly identified sequences in this work. All primers used are 9 
summarized in Table 1. Eight microliters of each PCR were analyzed by electrophoresis on a 1.8% 10 
agarose gel and visualized by ethidium bromide staining. Real Time quantitative Polymerase Chain 11 
Reaction (qPCR) was performed with Maxima SYBR Green/Fluorescein qPCR Master Mix (Thermo 12 
Scientific). An initial denaturation at 95°C for 10 min to activate Maxima Hot Start Taq DNA 13 
polymerase, was followed by 40 cycles of a two-step cycling amplification (95°C for 15 s, 60°C for 1 14 
min). The relative abundance of transcripts was calculated in arbitrary units (AU) using the formula 15 
235−cq (AU), where cq represents the quantification cycle. 16 
 17 
cDNA cloning 18 
Primers used for amplification of full-length cDNAs (CEACAM46a CEACAM46b CEACAM47, 19 
CEACAM49 CEACAM55) are summarized in table 1. These primers introduced HindIII or XhoI and 20 
XbaI or EcoRI restriction sites into the PCR products corresponding to the 5’- and 3’-ends of the mRNA, 21 
respectively. The full-length cDNA was digested with HindIII or XhoI and XbaI or EcoRI and cloned 22 
into the pRc/CMV or pEGFP-N3 expression vector. Plasmid DNA isolated from various clones were 23 
analyzed by PCR and sequencing. Nucleotide sequencing was performed with the BigDye Terminator 24 
Cycle Sequencing Kit (PE Applied Biosystems, Weiterstadt, Germany). 25 
 26 
Phylogenetic analyses 27 
Phylogenetic analyses based on nucleotide and amino acid sequences were conducted using MEGA 28 
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version 5. The Neighbor-Joining (NJ) method with bootstrap testing (100 or 1000 replicates) and 1 
Poisson correction was applied.  2 
 3 
CEACAM49 and PSG1 protein production and platelet assay 4 
Protein production and purification was done as described (Shanley et al. 2013) using transient 5 
transfection of pTT3CC49 and pTT3PSG1 vectors, respectively, into HEK-293 cells (Freestyle™ 293 6 
cells). The pTT3CC49 (pTT3CEACAM49) construct was generated by PCR amplifying the 7 
CEACAM49 CDS from pRc/CMV-ecaCEACAM49 incorporating 5’ EcoRI and 3’ HindIII restriction 8 
sites using the primers, ecaCEACAM49For: 5’-gGAATTCaccatgcaatcaccctca and 9 
ecaCEACAM49Rev: 5’-cAAGCTtggctctgtaactgggg. The PCR amplified band was blunt cloned into 10 
PSTBlue1 and sub-cloned into pTT3-B using EcoRI and HindIII restriction enzymes.  11 
 12 
To produce recombinant PSG1 and CEACAM49 proteins, endotoxin-free plasmid DNA was purified 13 
from bacterial cultures using the Endofree Plasmid Maxi Kit (Qiagen). All subsequent steps were carried 14 
out using confirmed endotoxin-free reagents and tissue culture flasks. The DNA was transiently 15 
transfected into Freestyle 293-F cells (Invitrogen) using Freestyle MAX reagent (Invitrogen). The 16 
Freestyle 293-F cells were grown in suspension in Freestyle 293 Expression Medium, by shaker culture, 17 
to a density of 1×106 cells per ml. The plasmid DNA was diluted in OptiPRO serum-free medium at a 18 
ratio of 1µg DNA in 20µL OptiPRO for every 1mL of cells. Freestyle MAX reagent was also diluted in 19 
OptiPRO at the same ratio (1µL Freestyle MAX reagent in 20µL OptiPRO per milliliter of cells). The 20 
diluted DNA and Freestyle MAX reagent were then combined, mixed gently, and incubated at room 21 
temperature (RT) for 20min. The mixture was added to the cell suspension and the cells were cultured 22 
for a further 72h. The culture was then centrifuged at 200g for 5min at RT to separate the protein-23 
containing medium from the cells, and the medium was frozen in aliquots at −80°C. 24 
Recombinant proteins were purified from cell culture medium using Qiagen Ni-NTA resin. Imidazole 25 
(Sigma) was added to the culture medium to a final concentration of 10mM to reduce non-specific 26 
binding. Ni-NTA resin was added to the medium at a ratio of 1ml resin suspension (corresponding to 27 
0.5mL resin bed volume) to 100mL medium. The medium and resin were then batch bound overnight 28 
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on a rotating wheel at 4°C. The medium and resin mix was then passed through a disposable 1 
polypropylene column (Pierce, Thermo Fisher Scientific) and the resin was washed with wash buffer 2 
(500mM NaCl, 20mM NaH2PO4, pH6) until the absorbance at 260nm reduced to 0. Protein was then 3 
eluted from the column with increasing concentrations of imidazole in wash buffer, usually 4×1.5ml 4 
50mM fractions, 5×1.5mL 200mM fractions, 4×1.5ml 300mM fractions and 3×1.5ml 500mM fractions. 5 
Fractions containing recombinant PSG1 or CEACAM49 were then pooled and passed through a new 6 
column containing 0.5ml Ni-NTA resin, the flow-through collected, and bound protein eluted with 1mL 7 
50mM imidazole followed by three 1mL 200mM imidazole fractions. The flow-through and three 8 
200mM fractions were pooled and concentrated to a volume of 4–6mL using a Millipore Amicon Ultra 9 
Ultracel 10K centrifugal filter (Millipore). The concentrate was then dialyzed against three changes of 10 
2L of phosphate-buffered saline (PBS) at 4°C. The protein was then further concentrated to a volume of 11 
1–2mL depending on the starting volume of culture medium. Protein was quantified by Bradford Assay 12 
or UV Spectroscopy, checked by polyacrylamide gel electrophoresis, tested for LPS contamination 13 
(Limulus Amebocyte Lysate QCL-1000; Cambrex BioScience, Germany), aliquoted, and frozen at 14 
−80°C. For size exclusion chromatography (SEC), 1–4mg purified recombinant protein was applied to 15 
a HiLoad 16/60 Superdex S200 prep grade column in a 1mL volume with a flow rate of 1mL/min using 16 
the Akta explorer system in PBS. Determination of 1mL fractions to pool was based on chromatogram 17 
peaks. Resultant protein solution was concentrated. TGFβ1 contamination level was determined by 18 
enzyme-linked immunosorbent assay (ELISA). 19 
Preparation of human platelets 20 
Platelets were collected into 0.15vol/vol acid-citrate dextrose (ACD; 75mM trisodium citrate, 124mM 21 
dextrose and 38mM citric acid) anticoagulant and washed. Briefly, blood was centrifuged at 150g for 22 
10min at RT. In order to avoid any contamination from the buffy coat, ∼0.5mL of the platelet-rich 23 
suspension above the buffy coat layer was left behind in the centrifugation tube. Platelet-rich plasma 24 
(PRP) was then acidified to pH6.5 with ACD and prostaglandin E1 (PGE1, 1mM) was added. The 25 
platelets were pelleted by centrifugation at 750g for 10min at RT. The supernatant was removed and the 26 
platelet pellet was gently resuspended in 130mM NaCl, 3mM KCl, 10mM trisodium citrate, 9mM 27 
NaHCO3, 6mM dextrose, 0.9mM MgCl2, 0.81mM KH2PO4 and 10mM Tris pH7.4 (JNL buffer). Platelet 28 
10 
 
count was adjusted to 3×108per mL using a Sysmex XE K-1000 counter (Toa Medical Electronics Co. 1 
Ltd, Kobe, Japan). Platelets were allowed to stand at RT for 45min to let PGE1dissipate. Calcium 2 
chloride (CaCl2, 1.8mM) was added to platelets immediately before use. 3 
Platelet integrin binding assay 4 
Platelet integrin interaction assay was done as described (Shanley et al. 2013). Briefly, 10µL of 5 
2.5mg/mL Oregon green-labeled Fibrinogen (OgFg; Invitrogen) was added to 20µL aliquots of 6 
washed platelet suspension along with the indicated concentrations of PSG1 or CEACAM49 in 7 
successive tubes. Dose–response curves were produced for all proteins using serial dilutions of 1:2 in 8 
the range 200 to 12.5µg/mL. All experiments were run in duplicate at least three times. The platelet 9 
suspension was vortexed and allowed to stand at RT for 10min before the addition of 3.4µM thrombin 10 
receptor activating peptide (TRAP, Bachem, UK), a dose known to produce a 50% maximal response 11 
as measured by aggregometry in pilot studies. Assay tubes were incubated at RT for a further 10min. 12 
The reaction was stopped by addition of 1mL ice-cold buffer. In a separate series of experiments, 13 
250nM U46619 (Tocris Bioscience, UK), 10µM ADP (Bio/Data Corporation, UK), or 25µM 14 
epinephrine (Bio/Data Corporation, UK) were used to activate platelets. The association of OgFg with 15 
platelets was detected using a fluorescence-activated cell sorter (Becton Dickinson, Franklin Lakes, 16 
NJ, USA). Data acquisition and analysis were performed with the Cell Quest program. Platelet 17 
populations were gated, and histograms of mean fluorescence were generated for each sample. 18 
Statistical analysis was performed on the geometric scale. 19 
Results 20 
The equine CEA gene family cluster   21 
The complete equine CEA gene family cluster was identified as described in “materials and methods”. 22 
Surprisingly, only genes orthologous to CEACAM1, CEACAM16 and CEACAM19 exist; none 23 
orthologous gene to CEACAM18 and CEACAM20 could be identified. On the other hand a large number 24 
(30) of CEACAM1-related leader and N domain exons evolved in the horse genome. Further analysis 25 
indicated that 17 CEACAM1-related genes appear to be functional (named CEACAM1, CEACAM41-26 
56) and 13 of the CEACAM1-related genes appear to be pseudogenes (named CEACAMps1-13) (data 27 
not shown). Based on the most recent assembly of the horse genome (EquCab2) these genes are split 28 
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into two loci by the insertion of a chromosomal region flanked by LIPE and CD79A. Similar numbers 1 
of CEACAM1-related genes were only found in species which contain PSG genes. This finding 2 
prompted us to further analyze the possible structure of the CEACAM1-related CEACAMs of the horse.    3 
 4 
Multiple equine CEACAMs do not contain a transmembrane region 5 
It is assumed that the main structural difference of CEACAMs concerning their function is based on the 6 
mode of their membrane anchorage. Already known CEACAMs are either type I transmembrane 7 
proteins, GPI-anchored or secreted proteins. With very few exceptions secreted CEACAMs are PSGs. 8 
 9 
To predict the structure of equine CEACAMs we identified exons of CEACAM1-related genes and 10 
determined their open reading frames. Eight CEACAM genes contain an exon which codes for a 11 
transmembrane domain (TM exon), two of the TM exons contain a stop codon, which shortens the 12 
cytoplasmic part of the encoded domain and one has a mutation leading to a disabled splice acceptor 13 
side, indicating that this exon is not part of the processed mRNA (Fig. 2). None of the pseudogenes 14 
contains a TM exon (data not shown). In one gene (CEACAM41) the TM exon is followed by 4 exons 15 
together encoding a cytoplasmic domain (Cyt exons) possessing an immunoreceptor tyrosine-based 16 
activation motifs (ITAM) like motif. Four genes (CEACAM1, 42, 43, 50) contain Cyt exons which code 17 
for one immunoreceptor tyrosine-based inhibition motif (ITIM) and one immunoreceptor tyrosine-based 18 
switch motif (ITSM). In CEACAM42, however, the first Cyt exon has no functional splice donor site. 19 
No indications were found for the existence of GPI-anchored equine CEACAMs. Remakably, seven 20 
genes (CEACAM44, 46, 47, 48, 49, 52, 55) lack a transmembrane domain encoding exon and are 21 
composed of a leader, a N domain and an IgC domain (A2-type) exon. In all these genes the third exon 22 
contains a stop codon. Since all equine CEACAMs contain a leader exon the gene products without a 23 
transmembrane domain are assumed to be secreted proteins (Fig. 2). 24 
 25 
 26 
Phylogeny of CEACAMs in the horse 27 
Phylogenetic trees were constructed from nucleotide sequences of the TM-, IgV-, and IgC-exons. Two 28 
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types of TM exons were identified. One (CEACAM41) is connected with Cyt exons encoding an ITAM-1 
like motif and six which were related to the TM exon typically found in CEACAM1 genes which have 2 
ITIM/ITSM-encoding exons (Fig. 3A). We have previously reported that IgV-like domains of 3 
CEACAMs with ITAM-containing supposedly activating cytoplasmic tails are closely related to IgV-4 
like domains of inhibitory CEACAMs forming receptor pairs (Kammerer and Zimmermann 2010). 5 
Again in the present study we found that the IgV-like domain of the activating CEACAM41 is most 6 
similar to the IgV-like domains of the inhibitory receptors (CEACAM1, and CEACAM43) (Fig. 3B). 7 
Surprisingly, the IgV-like domains of secreted CEACAMs did not form one group as previously 8 
recognized for the IgV-like domains of PSGs in humans and rodents. In the horse two different groups 9 
of N domains of the secreted CEACAMs could be identified. The first is a sister group to the membrane 10 
bound CEACAMs and the second, including CEACAM47, CEACAM48 and CEACAM49, forms a 11 
group separated from all other CEACAM1-related CEACAMs. These findings may indicate that two 12 
different groups of secreted CEACAMs exist which may have different functions (Fig. 3B). The 13 
arrangement of the IgC-like domains of membrane bound CEACAMs is as in CEACAM1, starting with 14 
an A1 type domain followed by a B domain and an A2-type IgC-like domain. Interestingly, all secreted 15 
CEACAMs contain an A2-type IgC-like domain exon, which comprises a stop-codon and the 3’-16 
untranslated region.  17 
 18 
Generation of secreted CEACAMs in the horse 19 
Secreted CEACAMs in the horse belong to the CEACAM1-related CEACAMs as previously found in 20 
humans and rodents. They are, however, not found in all mammalian species (Kammerer & 21 
Zimmermann 2010). During evolution, secreted CEACAMs could have been generated by duplication 22 
of membrane anchored CEACAM1. Different truncations may account for the loss of membrane 23 
anchorage of these CEACAMs in different species. Based on genomic data, generation of secreted 24 
CEACAMs in the horse was caused either by the introduction of one or more stop codons into the A2 25 
exons or by mutation of a splice donor site of A2 domain exons. This interpretation was verified by 26 
sequencing cloned cDNAs generated from equine mRNAs (Fig. 4). In order to get experimental support 27 
for the prediction that CEACAMs without membrane anchorage are secreted, we selected four of them 28 
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and generated plasmids which encode CEACAM-GFP fusion proteins and transfected HEK-293 cells 1 
with these plasmids. As shown in Fig. 5, fusion proteins were detected in the cytoplasm of the cells in a 2 
diffuse staining pattern (Fig. 5B). Fusion proteins could further be detected in the culture supernatant of 3 
transfected cells and the amount of fusion proteins correlated with the time of culture consistent with 4 
these proteins being actively secreted by transfected cells (Fig. 5C). 5 
 6 
Secreted CEACAMs are expressed by trophoblast cells 7 
Next we identified tissues in which secreted equine CEACAMs are expressed. We generated gene 8 
specific primers for CEACAM44, 46, 47, 48, 49, 52, 55 and analyzed their expression by RT-PCR in 9 
29 different equine tissues (see “Materials and Methods”). PSG-like CEACAMs were detected in a 10 
restricted number of tissues including, Endometrial cups, freshly isolated and IL-2-stimulated PBMC, 11 
lymph node, salivary gland, tongue and ovary (Fig. 6). CEACAM46 was only detected in peripheral 12 
blood mononuclear cells and CEACAM52 was not detected in any of the tissues tested. Five secreted 13 
CEACAMs (CEACAM44, 47, 48, 49, 55) were expressed in trophoblast cells or placental tissues at one 14 
or more stages of pregnancy with expression patterns differing between CEACAMs both spatially and 15 
temporally (Fig. 7). CEACAM44 was strongly expressed in day 34 conceptus tissues (chorionic girdle, 16 
allantochorion and chorion) as well as day 31, 32 and 34 cultured chorionic girdle trophoblast (all 17 
passage 0) and endometrium. CEACAM47 was only weakly expressed in day 32 and day 34 freshly 18 
isolated and cultured trophoblast cells but not in day 34 conceptus tissues or day 65 endometrial cups. 19 
CEACAM48 was weakly expressed in day 32 cultured trophoblast and day 65 endometrial cups but 20 
again not in any of the day 34 conceptus tissues. CEACAM49 was strongly expressed in day 34 21 
chorionic girdle and cultured day 34 chorionic girdle trophoblast cells (both passage 0 and 3) and 22 
expression was maintained in day 65 endometrial cups. CEACAM55 was only expressed in day 65 23 
endometrial cup and at a low level in PBMC of some horses. Although day 65 endometrial cup tissue 24 
may be infiltrated with lymphocytes, it is plausible that CEACAM55 expression detected in the 25 
endometrial cup tissue was due to the trophoblast cells as opposed to the expression by infiltrating 26 
lymphocytes since CEACAM46 which is preferentially expressed by leucocytes was not detected in 27 
endometrial cups (Fig 7. And data not shown). Together, these results provide supporting data that 5/7 28 
14 
 
secreted CEACAMs are PSGs.  1 
 2 
To determine whether CEACAM44 and/or CEACAM49 expression was  enriched in trophoblast cells, 3 
we then quantified their expression using qRT-PCR in matched day 34 conceptus tissue (n=3), cultured 4 
purified chorionic girdle cells (n=5), endometrium (n=3) and PBMCs (n=3). Highest expression of 5 
CEACAM44 was noted in the purified cultured passage 0 day 32 and 34 chorionic girdle trophoblast 6 
cells and day 34 chorionic girdle tissue (Fig.7). CEACAM49 expression was very specific to trophoblast 7 
tissue or cultured trophoblast cells. No significant expression was found in endometrial tissue or PBMC. 8 
In contrast to CEACAM44, CEACAM49 was expressed to a similar amount in all three different 9 
trophoblast tissues (chorionic girdle, chorion and allantochorion).   10 
 11 
Horse PSG-like CEACAM49 has similar anti-platelet activity to human PSG1 12 
CEACAM49 turned out to be expressed in both the chorionic girdle cells and the endometrial cups, 13 
indication that this PSG-like CEACAM may have a pivotal function. To assay the functionality 14 
CEACAM49 was subcloned from pRcCMV-ecaCEACAM49 into the pTT3 expression vector 15 
incorporating a C-terminal V5-6xHis tag (Shanley et al. 2013). This allowed the generation and 16 
purification of CEACAM49 protein by transient transfection of the human HEK cell line using the 17 
Freestyle™293 expression system. Eluted and dialyzed aliquots of CEACAM49 from a nickel affinity 18 
chromatography column were combined and further purified by size exclusion chromatography to 19 
remove unidentified high molecular weight bands and contaminating TGFß1 (Ballesteros et al. 2015) 20 
(Fig. 8A-C). To determine whether CEACAM49 exhibits similar functionality to human PSG1, the 21 
CEACAM49 protein was applied to a fluorescent fibrinogen-platelet interaction assay as described 22 
(Shanley et al. 2013). CEACAM49 inhibited fibrinogen binding to TRAP-activated platelets in a dose-23 




In this study, we have characterized the CEA gene family of the horse. Unlike all other mammals 28 
15 
 
previously investigated, we found no evidence of conserved orthologs of human CEACAM18 and 1 
CEACAM20 in the horse genome (Kammerer & Zimmermann 2010), consistent with the findings of a 2 
recently published independent study (Pavlopoulou & Scorilas 2014). Nevertheless, other CEACAM1-3 
related CEACAM genes in the horse were identified and expanded significantly to probably 17 functional 4 
genes and 13 pseudogenes. Such a high number of CEACAMs has previously been found only in species 5 
which have an expanded PSG gene cluster (Kammerer & Zimmermann 2010). However, no orthologous 6 
relationship based on synteny or common structure could be identified for the horse PSG-like 7 
CEACAMs, indicating their independent evolution from a horse CEACAM1-like ancestor rather than a 8 
common PSG-like ancestor. The horse PSG-like CEACAMs are very different from PSGs in other 9 
species being composed solely of a single IgV-like N domain. Furthermore, there is significant variation 10 
in the predicted number of glycosylation sites between the equine family members, much more than is 11 
evident in the N or N1 domains of primate and rodent PSGs, respectively. This variation could reflect a 12 
diversification in function among horse PSG family members.  13 
 14 
Until now PSGs have only been identified in mammals which have a hemochorial placenta e.g., higher 15 
primates and rodents. Hemochorial placentas are characterized by direct contact of fetal cells with the 16 
maternal blood and immune system. Therefore, potent tolerance mechanisms are required to prevent 17 
destruction of fetal cells. Since PSGs have the capacity to modulate maternal immune responses 18 
(Martinez et al. 2012, Martinez et al. 2013, Falcon et al. 2014) we previously suggested that 19 
maintenance of immune tolerance is an important selective force in the expansion of PSG gene clusters 20 
(Kammerer & Zimmermann 2010).  The horse has, similar to swine and cattle, an epitheliochorial 21 
placenta in which fetal cells are separated from the maternal immune system. In addition, the recruitment 22 
of maternal immune cells into epitheliochorial placentas is very limited compared to hemochorial 23 
placentas (Carter & Enders 2013). However, the horse is exceptional in that in this species, the 24 
specialized chorionic girdle cells of the conceptus invade into the endometrium of the mare to form the 25 
endometrial cups. The dndometrial cups are recognized by maternal T-cells due to their expression of 26 
MHC class I antigens. A large number of CD4+ and CD8+ T-cells infiltrate the endometrial stroma at 27 
the edge of endometrial cups (de Mestre et al. 2010), and by day 60–70, these cells move into the cup. 28 
16 
 
Over the next 30 days or so, neutrophils, macrophages, and eosinophils also invade into the main area 1 
of the cup. The cups become necrotic and are eventually sloughed between days 100 and 140 in most 2 
mares. Although the immune cells are present, there is evidence that they do not attack the cup cells, 3 
and the mechanism of the demise of the cups is currently unclear. However, despite such a close contact 4 
with maternal immune cells, semiallogeneic fetal cells are not attacked, indicating that powerful 5 
tolerance mechanisms are at work (Noronha & Antczak 2010).  6 
 7 
Several immune tolerance mechanisms during pregnancy were recently identified in primates and 8 
rodents, including downregulation of classical MHC class I antigens, upregulation of indoleamine 2,3-9 
dioxygenase (IDO) which causes a local depletion of tryptophan, and upregulation of CD95L (Fas 10 
ligand) that promotes apoptosis of activated lymphocytes (Trowsdale & Betz 2006). Additional poorly 11 
characterized secreted factors are likely to participate in tolerance induction during pregnancy 12 
(Trowsdale & Betz 2006). PSGs may represent such factors inducing immunotolerance and 13 
thromboregulation, in human and mice (Moore & Dveksler 2014, Ballesteros et al. 2015). Thus, we 14 
speculate that equine PSG-like CEACAMs expressed by infiltrating chorionic girdle trophoblast and 15 
endometrial cup cells may have a similar function controlling activity of T cells located at the borders 16 
of endometrial cups, and perhaps on peripheral T cells. Indeed, peripheral blood lymphocytes from 17 
pregnant mares have a reduced capacity to develop into effective cytotoxic T cells (Baker et al. 1999). 18 
PSGs have the potential to be present in maternal blood, as one of the major secretions of endometrial 19 
cups is equine chorionic gonadotropin, which is found at very high levels in the blood of pregnant mares 20 
while the cups persist (Allen 2001). Although additional work is needed to verify putative 21 
immunoregulatory functions of PSGs, in this study, we did confirm that PSG-like equine CEACAM49, 22 
similar to human and mouse PSGs, inhibits the interaction between activated platelets and fibrinogen 23 
(Shanley et al. 2013). An anti-platelet activity may be beneficial for endometrial cup function because 24 
at the base of endometrial cups there are many newly formed lymph and blood vessels to support 25 
constant circulation in this immature capillary bed (Antczak et al. 2013). In addition, PSGs have been 26 
shown to bind other integrins, besides platelet integrin (Moore & Dveksler 2014), and it is possible that 27 
this also occurs in the horse. Therefore, a PSG-integrin interaction may have additional yet unknown 28 
17 
 
benefits for the function and/or survival of endometrial cups. Thus equine PSGs have important 1 
functional similarities with human and mouse PSGs indicating that they were generated independently 2 
by convergent evolution. 3 
 4 
There is probably no recent common PSG ancestor from which the PSGs in different species evolved. 5 
Lack of synteny suggests that PSGs evolved independently in different mammalian species. As a 6 
consequence PSGs structurally differ between primates, rodents and perissodactyls. Nevertheless, 7 
molecular interaction of PSGs with integrins is found in all mentioned orders. This striking similarity 8 
may be explained by an interaction via the N-terminal IgV-like domain which is present in all types of 9 
PSGs. Interaction with integrins could be part of the core functional requirements for the selection of 10 
PSGs gene expansion. Whether regulation of immunity belongs also to these core functions, has to be 11 
confirmed in further studies. Remarkably, the horse is an exceptionally well suited animal model to 12 
address such a question, since mares mount a strong systemic (antibody) and local (cellular) immune 13 
response to paternal antigens (Noronha & Antczak 2010). This naturally occurring immune recognition 14 
will be beneficial for the determination of the immune regulatory function of PSGs. Whatever the core 15 
functions of PSGs are, there must be an extremely strong selection pressure to select for the expansion 16 
of the PSG cluster in disparate species either for diversification and functional fine tuning or for increase 17 
of the dose of highly similar proteins. Among the 12 protein-coding genes with the highest level of 18 
enriched expression in human placenta compared to other tissues are eight PSG genes (Uhlen et al. 19 
2015). A better understanding of PSG function in horses may have important implications for the 20 
elucidation of the role of PSGs in human pregnancy. 21 
 22 
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Figure Legends 1 
Figure 1 - Genomic arrangement of the extended Leukocyte Receptor Complex and the 2 
CEACAM/PSG locus in the horse. 3 
 4 
The CEACAM/PSG cluster is located on horse chromosome 10 within the extended leukocyte receptor 5 
complex (LRC). The extended LRC is limited on both ends by the genes coding for adaptor proteins and 6 
the Leukocyte receptor complex, respectively. Loci containing genes of the CEACAM1-related 7 
CEACAMs are shown in yellow and the locus containing the conserved CEACAM genes are shown in 8 
blue. Lower part: Genomic organization of horse CEA gene family loci. Arrowheads represent genes 9 
with their transcriptional orientation. CEACAM pseudogenes are shown in yellow and named in black. 10 
Putatively intact CEACAM genes are shown in orange and named in bold (secreted CEACAMs in red 11 
and membrane anchored in black). SIGLEC genes and marker genes are shown as black arrowheads. 12 
The scale indicated by dots is 1 Mbp unless interrupted by slanted lines. The horse Ensembl/NCBI 13 
release EquCab2 was used. Nucleotide numbering of the chromosomes starts at the centromere. CCps, 14 
CEACAM pseudogenes; CC, CEACAM; chr, chromosome. 15 




Figure 2 – Prediction of CEA gene family members from sequence analyses of the horse genome.  1 
Exon arrangement of equine CEACAM1-related genes. The exon types are indicated by differently 2 
colored boxes. Leader exons are shown as gray, IgV-like domain exons as red, IgC-like domain exons 3 
as blue and transmembrane domain exons as black boxes. The exons encoding the cytoplasmic domain 4 
with an ITIM or an ITAM motif are shown in yellow and green, respectively. The presence of nonsense 5 
mutations, deletions/insertions in exons causing reading frame shifts are indicated by asterisks. Two 6 
genes with intact ITIM/ITSM were identified and named CEACAM1 and CEACAM43. No leader exon 7 
could be identified for CEACAM51 because of a sequence gap in the publicly available genomic 8 
sequences. The genes are arranged in the order and orientation as found on horse chromosome 10. C1-9 
C4, cytoplasmic domain exons; L, leader exon; TM, transmembrane exon; ~ mutation of splice sites. 10 
 11 
 12 




Phylogenetic trees were constructed from transmembrane domain exon (A), IgV-like domain exon (B) 2 
and IgC-like domain exon (C) nucleotide sequences from CEACAM members of the horse using the 3 
UPGMA method (MEGA 6.0 software). The reliability of a phylogenetic tree was assessed using the 4 
Bootstrap test applying 500 replicates. The statistical support for selected nodes is shown. Bootstrap 5 
values >50 are shown. CEACAM46a and CEACAM46b are putative allelic CEACAM46 variants. 6 




Figure 4 – Mechanisms for generation of secreted CEA family members in the horse. 1 
 2 
Secreted CEACAMs in the horse are formed by two different mechanisms: firstly by inclusion of A2-3 
type domain exons (exon 3), which contain multiple stop codons and secondly by mutation of the splice 4 
donor site at the end of the N domain exon, leading to read through into the following intron. CEACAMs 5 
from which the structure was verified by cloning are underlined. Stop codons are shown in red. 6 
Homologous codons of other CEACAMs representing non-stop codons are indicated in blue. The 7 




Figure 5: PSG-like CEACAMs are secreted by eukaryotic cells.  1 
 2 
 (A) Schematic illustration of the proteins used in the study. CEACAM46a, CEACAM46b, 3 
CEACAM47, and CEACAM55 were expressed in human cells as GFP fusion proteins. (B) Expression 4 
of CEACAM46a-eGFP fusion protein by transfected and sorted HEK-293A cells. GFP fusion proteins 5 
are only present in the cytoplasm not in the nucleus as wild type GFP or at the cell surface as membrane 6 
anchored CEACAMs. (C) Western blot analysis to detect secreted CEACAM-eGFP fusion proteins in 7 
the culture supernatant of transfected HEK-293A cells. Supernatant of untransfected HEK-293A cells 8 
was used as control. Upper panel: the amount of fusion proteins in the culture supernatant increased 9 
with time of culture. For positive control of eGFP detection cell extracts of eGFP transfected HEK-10 
293A cells were used.  Lower panel: All constructs accumulate in the culture medium. CC46a, 11 
CEACAM46_eGFP; CC46b, CEACAM46b_eGFP; CC47, CEACAM47_eGFP; CC55, 12 
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CEACAM55_eGFP; Sup, supernatant; UB, unspecific binding; FP, fusion protein;  1 
 2 
Figure 6 - Horse PSG-like CEACAMs are preferentially expressed in PBMC and endometrial 3 
cups. 4 
 5 
Total RNA was isolated from various equine tissues as described in “Material and Methods”. Biopsies 6 
of endometrial cups were taken on day 65 of pregnancy. Lymphocytes were isolated from peripheral 7 
blood of healthy horses some of these lymphocytes were cultured in the presence of recombinant human 8 
IL-2 for 14 or 19 days (d). In additional 25 equine tissues (“Materials and Methods”) none of these 9 
mRNAs were detected. Gene-specific primers used in these experiments are summarized in Table 1. 10 




Figure 7 – Horse PSG-like molecules are expressed in trophoblast cells. 1 
 2 
A. Qualitative RT-PCR analysis of expression of secreted CEACAMs in day 34 conceptus tissues (n=3), 3 
cultured day 31-34 chorionic girdle trophoblast cells either isolated without prior passaging (P0) or 4 
isolated after 3 passages (P3) (n=5), non-pregnant endometrium (n=4) and PBMC isolated from non-5 
pregnant mares (n=3). Amplicons were generated using primers specific for equine CEACAM44, 46, 6 
47, 48, 49, 55, and β-ACTIN (as control) mRNA, and all bands observed in all tissues with each primer 7 
set are of the correct predicted size (table 1). CG=chorionic girdle, AC=allantochorion, 8 
EM=Endometrium, H20 = no template control. B. and C. Real time qRT-PCR expression of 9 
CEACAM44 (B) and CEACAM49 (C) mRNA in three independent day 34 conceptus tissues, chorionic 10 
girdle (CG), chorion (Ch), allantochorion (AC) as well as cultured day 32 and 34 chorionic girdle 11 
trophoblast cells (n=2). Data points represent the mean +/- the SE of two experimental replicates.  12 
Figure 8 – Horse PSG-like CEACAM49 has similar anti-platelet activity to human PSG1.  13 
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 (A) Chromatogram of 1 
equine CEACAM49 applied to a Superdex 200 prep grade size exclusion column with red box indicating 2 
fractions that were pooled and concentrated. (B) Coomassie stained 12% polyacrylamide gel with 8 µg 3 
of indicated protein per lane. (C) TGFβ1 ELISA of SM and post-SEC equine CEACAM49 preparations. 4 
(D) FACS analysis showing fluorescent Oregon Green Fibrinogen (OGFg) binding to resting and 5 
thrombin receptor activating peptide (TRAP)-activated human platelets with, and without, 200 µg/ml 6 
human PSG1 or equine CEACAM49 pre-treatment. (E) Graphs of dose-dependent inhibition of OGFg 7 
binding to activated human platelets, relative to untreated controls, by human PSG1 and equine 8 
CEACAM49. n = 3; One-way ANOVA; **, P<0.01; ***, P<0.001. SM, starting material; SEC, size 9 





Table 1: Gene-specific oligonucleotides for expression analyses and cDNA cloning of horse CEA 2 
gene family members 3 
gene 










































































































CEACAM46a For: TCTTCTCACAGAGGGGAGGA 











CEACAM47 For:   CCAGGCTCTTCTCACAGAGG 




CEACAM49 For:   CCAAGCTCTTCTCACAGACG 




CEACAM55 For: GGGCATAAGCTCTTCTCACG 




ND, not done; NA, not applicable; For: forward primer; Rev: reverse primer 1 
  2 
